On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2: Annals of Oncology

O. Caffo, V. Zagonel, C. Baldessari, A. Berruti, R. Bortolus, S. Buti, G.L. Ceresoli, M. Donini, P. Ermacora, G. Fornarini, L. Fratino, C. Masini, F. Massari, A. Mosca, C. Mucciarini, G. Procopio, M. Tucci, E. Verri, P. Zucali, C. Buttigliero

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1415-1416
Number of pages2
JournalAnn. Oncol.
Volume31
Issue number10
DOIs
Publication statusPublished - 2020

Keywords

  • abiraterone
  • cabazitaxel
  • docetaxel
  • enzalutamide
  • antiandrogen
  • androgen deprivation therapy
  • cancer mortality
  • cancer recurrence
  • cancer registry
  • castration resistant prostate cancer
  • coronavirus disease 2019
  • human
  • infection risk
  • Letter
  • priority journal
  • prostate cancer
  • Severe acute respiratory syndrome coronavirus 2
  • Betacoronavirus
  • Coronavirus infection
  • male
  • pandemic
  • prostate tumor
  • severe acute respiratory syndrome
  • virus pneumonia
  • Androgen Antagonists
  • Coronavirus Infections
  • Humans
  • Male
  • Pandemics
  • Pneumonia, Viral
  • Prostatic Neoplasms
  • Severe Acute Respiratory Syndrome

Cite this